Brought to you by 
Aldevron licenses Stanford's minicircle DNA technology for multiple myeloma
31 Mar 2017
Executive Summary
CMDO Aldevron licensed Stanford University's gene regulation technology for use in third-party development of multiple myeloma cell therapies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Synthesis Technologies, Production Processes
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com